Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 in EGFR T790M Positive NSCLC
NCT02094261Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started May 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02094261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094261.